Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance-Reference-Cited by-同舟云学术

Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance

Published:2017-05-18 Issue:1 Volume:65 Page:141-146
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Rex John H¹,Talbot George H²,Goldberger Mark J³,Eisenstein Barry I⁴,Echols Roger M⁵,Tomayko John F⁶,Dudley Michael N⁷,Dane Aaron⁸

Affiliation:

1. F2G, Ltd, Eccles, United Kingdom;

2. Talbot Advisors LLC, Anna Maria, Florida;

3. Mark Goldberger MD MPH LLC, Potomac, Maryland;

4. CARB-X, Boston, Massachusetts;

5. Infectious Disease Drug Development Consulting, LLC, Easton, Connecticut;

6. Spero Therapeutics, Cambridge, Massachusetts;

7. The Medicines Company, San Diego, California;

8. DaneStat Consulting, Macclesfield, United Kingdom

Funder

Wellcome Trust

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/65/1/141/24266431/cix246.pdf

Reference34 articles.

1. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues;Temple;Ann Intern Med,2000

2. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases;Ellenberg;Ann Intern Med,2000

3. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens;Infectious Diseases Society of America;Clin Infect Dis,2012

4. Efficient delivery of investigational antibacterial agents via sustainable clinical trial networks;McDonnell;Clin Infect Dis,2016

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Facile encapsulation of glabridin in Zeolitic Imidazolate Framework-8 (ZIF- 8): Characterization, antibacterial activity and in-vitro drug release;2024-04-05

2. Deciphering the scope of in silico screening of novel natural lead molecules against putative molecular targets of multidrug-resistant bacterial pathogens;Nanotechnology and In Silico Tools;2024

3. An overview of gram-negative bacteria with difficult-to-treat resistance: definition, prevalence, and treatment options;Expert Review of Anti-infective Therapy;2023-10-09

4. Value assessment of antimicrobials using the STEDI framework – How steady is the outcome?;Health Policy;2023-10

5. The versatile defender: exploring the multifaceted role of p62 in intracellular bacterial infection;Frontiers in Cellular and Infection Microbiology;2023-05-05